Cellectis S.A. (CMVLF)
USD 2.54
(0.0%)
USD 2.54
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -92.63 Million USD | -0.31% |
| 2022 | -76.37 Million USD | -4.95% |
| 2021 | -83.14 Million USD | 0.0% |
| 2020 | -34.68 Million USD | 30.85% |
| 2019 | -113.5 Million USD | -17.57% |
| 2018 | -90.88 Million USD | -13.43% |
| 2017 | -89.51 Million USD | -44.85% |
| 2016 | -65.31 Million USD | -123.48% |
| 2015 | -25.68 Million USD | -545.54% |
| 2014 | 337.6 Thousand USD | -478.62% |
| 2013 | 1.17 Million USD | 104.48% |
| 2012 | -26.13 Million USD | -6.68% |
| 2011 | -24.5 Million USD | -88.77% |
| 2010 | -12.98 Million USD | -26.75% |
| 2009 | -12.25 Million USD | -221.53% |
| 2008 | -3.19 Million USD | 47.69% |
| 2007 | -6.08 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -18.22 Million USD | 122.82% |
| 2024 Q2 | -19.16 Million USD | -307.23% |
| 2023 Q1 | -18.2 Million USD | -221.55% |
| 2023 Q3 | -16.55 Million USD | 30.01% |
| 2023 Q4 | -26.23 Million USD | -58.47% |
| 2023 Q2 | -23.65 Million USD | -29.99% |
| 2023 FY | - USD | -0.31% |
| 2022 Q4 | -5.66 Million USD | 82.93% |
| 2022 Q1 | -26.66 Million USD | 31.92% |
| 2022 Q2 | -28.96 Million USD | -8.65% |
| 2022 Q3 | -33.16 Million USD | -14.48% |
| 2022 FY | - USD | -4.95% |
| 2021 Q4 | -39.16 Million USD | -3.06% |
| 2021 Q1 | -10.44 Million USD | 73.34% |
| 2021 FY | - USD | 0.0% |
| 2021 Q2 | -34.07 Million USD | -226.34% |
| 2021 Q3 | -38 Million USD | -11.53% |
| 2020 Q1 | 20.04 Million USD | 152.06% |
| 2020 FY | - USD | 30.85% |
| 2020 Q2 | -30.88 Million USD | -254.13% |
| 2020 Q3 | -26.78 Million USD | 13.3% |
| 2020 Q4 | -39.16 Million USD | -46.24% |
| 2019 Q4 | -38.49 Million USD | -54.44% |
| 2019 Q3 | -24.92 Million USD | 25.45% |
| 2019 FY | - USD | -17.57% |
| 2019 Q2 | -33.43 Million USD | -54.87% |
| 2019 Q1 | -21.59 Million USD | 26.22% |
| 2018 Q4 | -29.26 Million USD | -2.92% |
| 2018 FY | - USD | -13.43% |
| 2018 Q3 | -28.43 Million USD | -35.01% |
| 2018 Q2 | -21.06 Million USD | 9.13% |
| 2018 Q1 | -23.17 Million USD | 16.52% |
| 2017 FY | - USD | -44.85% |
| 2017 Q1 | -16.22 Million USD | 18.09% |
| 2017 Q2 | -19.9 Million USD | -22.69% |
| 2017 Q3 | -25.09 Million USD | -26.04% |
| 2017 Q4 | -27.76 Million USD | -10.64% |
| 2016 Q4 | -19.81 Million USD | -60.24% |
| 2016 FY | - USD | -123.48% |
| 2016 Q2 | -10.64 Million USD | 52.86% |
| 2016 Q1 | -22.58 Million USD | -1811.82% |
| 2016 Q3 | -12.36 Million USD | -16.1% |
| 2015 Q1 | -3.49 Million USD | -11691.17% |
| 2015 Q4 | 1.31 Million USD | 109.03% |
| 2015 FY | - USD | -545.54% |
| 2015 Q3 | -14.62 Million USD | -11.75% |
| 2015 Q2 | -13.08 Million USD | -274.18% |
| 2014 FY | - USD | -478.62% |
| 2014 Q4 | -29.65 Thousand USD | -105.35% |
| 2014 Q3 | 554.67 Thousand USD | 118.9% |
| 2014 Q2 | -2.93 Million USD | 0.64% |
| 2014 Q1 | -2.95 Million USD | 40.83% |
| 2013 Q2 | -9.28 Million USD | -1.46% |
| 2013 FY | - USD | 104.48% |
| 2013 Q1 | -9.14 Million USD | 0.0% |
| 2013 Q3 | -4.9 Million USD | 47.14% |
| 2013 Q4 | -4.99 Million USD | -1.75% |
| 2012 FY | - USD | -6.68% |
| 2012 Q4 | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2011 FY | - USD | -88.77% |
| 2010 FY | - USD | -26.75% |
| 2009 FY | - USD | -221.53% |
| 2008 FY | - USD | 47.69% |
| 2007 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | -30.407% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | -1462.446% |
| SQZ Biotechnologies Company | -64.14 Million USD | -44.426% |
| Evofem Biosciences, Inc. | -17.37 Million USD | -433.31% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 198.509% |
| Mesoblast Limited | -62.38 Million USD | -48.48% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -5930.797% |
| Genus plc | 73.7 Million USD | 225.693% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | -1301.131% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | -2511.673% |
| Marizyme, Inc. | -34.28 Million USD | -170.222% |
| ContraFect Corporation | -64.99 Million USD | -42.519% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | -956.042% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | -1946.664% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -6508.323% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | -3403.037% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -3886.367% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -17781.81% |
| Accustem Sciences Inc. | -3.74 Million USD | -2372.655% |
| RVL Pharmaceuticals plc | -48.22 Million USD | -92.083% |
| EV Biologics, Inc. | -1.26 Million USD | -7210.683% |
| Q BioMed Inc. | -617.62 Thousand USD | -14898.672% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 2693.393% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -14548.185% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -3954.999% |
| Biomind Labs Inc. | -1.03 Million USD | -8854.24% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 1037.896% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | -1193.569% |
| Skye Bioscience, Inc. | -13.54 Million USD | -583.784% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -6127.999% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -370444.0% |
| Arch Therapeutics, Inc. | -3.88 Million USD | -2284.87% |
| IMV Inc. | -35.52 Million USD | -160.775% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | -483.727% |
| Curative Biotechnology, Inc. | -2.5 Million USD | -3602.534% |
| GB Sciences, Inc. | -1.41 Million USD | -6424.19% |
| Alpha Cognition Inc. | -9.7 Million USD | -854.459% |
| HST Global, Inc. | -5303.00 USD | -1746760.268% |
| CSL Limited | 4.78 Billion USD | 101.934% |
| Halberd Corporation | -74.27 Thousand USD | -124613.58% |
| Enzolytics Inc. | -2.12 Million USD | -4265.445% |
| Resverlogix Corp. | -11.74 Million USD | -688.929% |
| Affymax, Inc. | -14.29 Million USD | -548.031% |
| SYBLEU INC | -141.57 Thousand USD | -65334.305% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | -2924.339% |
| argenx SE | -216.02 Million USD | 57.118% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | -67.397% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 7711.832% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -6080.241% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 24552.281% |
| AVAX Technologies, Inc. | -6.11 Million USD | -1415.482% |
| Zenith Capital Corp. | -8.6 Million USD | -976.412% |
| Genscript Biotech Corporation | -248.71 Million USD | 62.755% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -531649.039% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | -3686.531% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -52526.807% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | -133.712% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | -3102.82% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | -8753.573% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 1377791.85% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -5193.489% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -4722.503% |
| BioStem Technologies, Inc. | -7.55 Million USD | -1126.375% |
| ONE Bio Corp. | 13.61 Million USD | 780.494% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -51055.239% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -4403.452% |
| Agentix Corp. | -1.37 Million USD | -6653.096% |
| LadRx Corporation | 412.28 Thousand USD | 22569.032% |
| Cell Source, Inc. | -4.27 Million USD | -2068.179% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -25126.226% |
| Regen BioPharma, Inc. | 1.46 Million USD | 6419.153% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -9786.984% |
| NovAccess Global Inc. | -1.03 Million USD | -8852.094% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 1146.285% |
| Itoco Inc. | -1.86 Million USD | -4856.461% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -24302.297% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -8200.717% |
| Kadimastem Ltd | -2.62 Million USD | -3429.823% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -38635.522% |
| CytoDyn Inc. | -18.02 Million USD | -413.817% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -117117.73% |
| Mobile Lads Corp. | -2.24 Million USD | -4033.397% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -757410.835% |
| Qrons Inc. | -40.08 Thousand USD | -231021.978% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -18973.543% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 17663.558% |
| Rebus Holdings, Inc. | -951 Thousand USD | -9640.904% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -8622.705% |
| International Stem Cell Corporation | 202 Thousand USD | 45959.406% |
| Bioxytran, Inc. | -3.82 Million USD | -2324.933% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -175880.243% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | -3662.736% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | -158.262% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -205757.778% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | -3283.346% |
| Neutra Corp. | -181.24 Thousand USD | -51010.363% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | -359.527% |
| PureTech Health plc | -11.62 Million USD | -696.732% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | -359.558% |
| IXICO plc | -707 Thousand USD | -13002.687% |
| IntelGenx Technologies Corp. | -7.68 Million USD | -1105.413% |
| Gelesis Holdings, Inc. | -48.34 Million USD | -91.61% |
| CSL Limited | 4.73 Billion USD | 101.957% |